Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can online therapy calm BRCA1/2 women's fear of cancer return?

NCT ID NCT06817694

Symptom relief Sponsor: CHU de Quebec-Universite Laval Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a 4-week online cognitive-behavioral therapy (CBT) program for women with BRCA1/2 mutations who have finished cancer treatment and still worry a lot about cancer coming back. Researchers will compare those who get therapy right away to those on a waitlist, measuring fear levels, anxiety, and quality of life. The goal is to see if this adapted therapy helps and if the effects last.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cognitive-behavioral group therapy
What this could lead to
If successful, this could provide an effective, accessible online therapy to help women with BRCA1/2 mutations manage fear of cancer recurrence and improve quality of life.
What could go wrong
This is a relatively small, early-stage trial comparing therapy to a waitlist, not a placebo. The therapy may not work for everyone, and benefits might not last long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\) Have completed primary treatment for breast or ovarian cancer (i.e., surgery, chemotherapy, and radiotherapy). * 2\) Be known to carry a BRCA1/2 pathogenic mutation. * 3\) Have a clinical level of fear of cancer recurrence as defined by a score of 13 or more on the Fear of Cancer Recurrence Inventory severity subscale. * 4\) Be at least 18 years of age. * 5\) Be able to read, understand and express herself in French. Exclusion Criteria: * 1\) Have distant metastases (in the case of ovarian cancer, only stages IV and IIIC will be excluded). * 2\) Be known to carry a BRCA1/2 "VUS" mutation. * 3\) Have a known cognitive disorder. * 4\) Have a known severe psychological disorder (e.g., psychotic disorder, bipolar disorder, substance abuse or dependence disorder). * 5\) Have already taken part in the original FCR group psychotherapy at the CHU de Québec. * 6\) Women taking psychotropic medication are eligible, but only if the dosage has been stable for at least one month.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA2 mutation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

BRCA2-related cancer predisposition breast cancer cancerophobia neoplasm ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA2 mutation Breast cancer susceptibility gene (BRCA1) mutation Fear of cancer recurrence

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Québec-Université Laval

    RECRUITING

    Québec, Quebec, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.